Literature DB >> 30713117

How safe is bariatric surgery in patients with class I obesity (body mass index 30-35 kg/m2)?

Xiaoxi Feng1, Amin Andalib2, Stacy A Brethauer1, Philip R Schauer1, Ali Aminian3.   

Abstract

BACKGROUND: The safety profile of bariatric surgery in patients with class I obesity, or body mass index ≥30 and <35 kg/m2, is a matter of concern among patients and physicians.
OBJECTIVE: To assess the safety profile of bariatric surgery in patients with class I obesity.
SETTING: The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) data set.
METHODS: The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program 2015 to 2016 data sets were queried for class I obesity patients who underwent primary bariatric procedures. The 30-day postoperative safety profile, predictors of adverse events, and comparison between Roux-en-Y gastric bypass (RYGB) versus sleeve gastrectomy (SG) were studied.
RESULTS: A total of 8628 cases with a mean preoperative body mass index of 33.7 ± 1.1 kg/m2 were analyzed: 1838 (21.3%) underwent RYGB, 6243 (72.4%) underwent SG, 530 (6.1%) underwent gastric banding, and 17 (.2%) underwent duodenal switch; 33.9% had diabetes and 75% had hypertension. The composite morbidity rate (defined as presence of any of 24 postoperative adverse events) for the entire cohort was 3.8%, and the serious morbidity rate (presence of any of 9 serious complications) was .7%. The 30-day mortality rate was .05% (4 cases). Presence of chronic kidney disease was found to be associated with higher composite and serious morbidity (composite morbidity: odds ratio 5.1, 95% confidence interval 2.22-11.71; serious morbidity: odds ratio 5.66, 95% confidence interval 1.52-21.14). SG patients had significantly better short-term safety outcomes than RYGB patients.
CONCLUSION: Findings from this study, the largest series to date, indicate that bariatric surgery is safe in patients with class I obesity, with very low risk of morbidity and mortality.
Copyright © 2018 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Body mass index; Complication; Diabetes; Gastric bypass; MBSAQIP; Metabolic surgery; Morbidity; Mortality; Obesity; Overweight; Safety; Sleeve gastrectomy

Mesh:

Year:  2018        PMID: 30713117     DOI: 10.1016/j.soard.2018.12.006

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  6 in total

Review 1.  Executive Summary: Collected Papers of the American College of Surgeons Metabolic Surgery Symposium.

Authors:  Henry Buchwald; J N Buchwald; Walter J Pories; David B Hoyt
Journal:  Obes Surg       Date:  2020-05       Impact factor: 4.129

2.  Quality of MBSAQIP data: bad luck, or lack of QA plan?

Authors:  K Noyes; A A Myneni; S D Schwaitzberg; A B Hoffman
Journal:  Surg Endosc       Date:  2019-06-12       Impact factor: 4.584

Review 3.  Endoscopic Evaluation and Management of Late Complications After Bariatric Surgery: a Narrative Review.

Authors:  Vivek Kumbhari; Carel W le Roux; Ricardo V Cohen
Journal:  Obes Surg       Date:  2021-07-30       Impact factor: 4.129

Review 4.  Nutritional Management in Bariatric Surgery Patients.

Authors:  Andrea Deledda; Stefano Pintus; Andrea Loviselli; Michele Fosci; Giovanni Fantola; Fernanda Velluzzi
Journal:  Int J Environ Res Public Health       Date:  2021-11-17       Impact factor: 3.390

5.  Comparison of Sleeve Gastrectomy vs Intensive Lifestyle Modification in Patients With a BMI of 30 to Less Than 35.

Authors:  Erik Stenberg; Gustaf Bruze; Johan Sundström; Claude Marcus; Ingmar Näslund; Johan Ottosson; Martin Neovius
Journal:  JAMA Netw Open       Date:  2022-07-01

6.  Predictors of normalized HbA1c after gastric bypass surgery in subjects with abnormal glucose levels, a 2-year follow-up study.

Authors:  Neda Rajamand Ekberg; Henrik Falhammar; Erik Näslund; Kerstin Brismar
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.